CHEK2 (Checkpoint Kinase 2, also known as CHK2) is a serine/threonine protein kinase that functions as a critical effector of the ATM-mediated DNA damage response pathway. Originally identified as a key regulator of cell cycle arrest following DNA double-strand breaks, CHEK2 has emerged as an important player in neurodegenerative diseases through its involvement in neuronal DNA repair, cell survival, and response to genotoxic stress [1].
This page provides comprehensive information about CHEK2's molecular structure, normal physiological functions, and its increasingly recognized role in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions.
CHEK2 is a 543-amino acid serine/threonine kinase with a molecular weight of approximately 61 kDa. The protein contains several distinct functional domains:
:: infobox .infobox-protein
| Protein Name | Checkpoint Kinase 2 |
| Alternative Names | CHK2, Cdc2-like kinase 2 |
| Gene | CHEK2 |
| Molecular Weight | 61 kDa |
| Length | 543 amino acids |
| UniProt ID | O96017 |
| Cellular Location | Nucleus (constitutively), translocates to DNA damage sites |
| Protein Family | CAMK (Ca2+/Calmodulin-dependent protein kinase) family |
| PDB Structures | 2CN5, 1GZS, 2JAM |
::
N-terminal SQ/TQ Cluster Domain: Contains multiple SQ/TQ motifs that serve as ATM phosphorylation sites. The critical Thr68 residue is the primary ATM phosphorylation site required for CHEK2 activation [2].
Kinase Domain (KD): The central catalytic domain (residues 220-400) exhibits serine/threonine kinase activity and shares homology with the kinase domains of other cell cycle regulators.
FHA Domain (Forkhead-Associated): Located at the C-terminus (residues 420-500), this phosphothreonine/phosphoserine-binding domain mediates protein-protein interactions essential for substrate recruitment and complex formation.
C-terminal Regulatory Domain: Contains the dimerization interface and additional regulatory phosphorylation sites.
CHEK2 activation follows a well-characterized cascade:
CHEK2 is a central effector of the DNA damage response:
Cell Cycle Arrest: CHEK2 phosphorylates CDC25A, CDC25B, and CDC25C phosphatases, leading to CDK inhibition and G1/S, G2/M arrest [3].
DNA Repair: CHEK2 phosphorylates BRCA1, promoting homologous recombination repair. It also activates XRCC1 and other repair factors.
Apoptosis Induction: CHEK2 phosphorylates p53 at Ser20, cooperating with ATM to activate p53-dependent apoptosis. It can also directly phosphorylate the pro-apoptotic proteins BAX and PUMA.
Transcription Regulation: CHEK2 phosphorylates transcription factors including E2F1, leading to activation of pro-apoptotic and DNA repair genes.
Beyond DNA damage, CHEK2 participates in:
CHEK2 dysregulation in AD involves multiple mechanisms:
1. DNA Damage Accumulation
Post-mortem AD brain tissue shows increased DNA damage and altered CHEK2 activation. Studies demonstrate that CHEK2-mediated checkpoint activation is elevated in AD brains, reflecting accumulated DNA damage [4].
2. Tau Pathology Interaction
CHEK2 activation has been reported in tauopathy models and human AD brains. Tau pathology may trigger DNA damage responses that involve CHEK2 activation [5].
3. Synaptic Dysfunction
DNA damage in neurons activates CHEK2, leading to synaptic gene repression. The DNA damage response in neurons can suppress activity-dependent gene expression critical for synaptic plasticity [6].
4. Mitochondrial Dysfunction
CHEK2 contributes to mitochondrial quality control through phosphorylation of mitochondrial proteins. Dysregulated CHEK2 in AD may contribute to mitochondrial dysfunction [7].
In PD models, CHEK2 contributes to disease pathogenesis through:
Dopaminergic Neuron Vulnerability: CHEK2-mediated DNA damage responses may be particularly relevant in dopaminergic neurons, which have high metabolic demands and are selectively vulnerable in PD [8].
LRRK2 Interaction: Evidence suggests cross-talk between LRRK2 and DNA damage response pathways. LRRK2 mutations may sensitize neurons to CHEK2-mediated growth arrest.
Mitochondrial DNA Damage: PD toxins (MPTP, 6-OHDA) induce mitochondrial DNA damage that activates CHEK2.
Neuroinflammation: Microglial CHEK2 may participate in the inflammatory response to DNA damage in PD.
While less studied, CHEK2 may contribute to FTD through:
CHEK2 has been implicated in ALS through:
CHEK2 presents both opportunities and challenges for therapy:
CHEK2 Inhibitors: Small molecule CHEK2 inhibitors (e.g., AZD7762, CHIR-124) are being developed for cancer therapy. In neurodegeneration, excessive CHEK2 activation may be harmful, suggesting potential benefit from inhibition [9].
CHEK2 Activators: Alternatively, enhancing CHEK2-mediated DNA repair in neurons may be beneficial in diseases characterized by DNA repair deficits.
Combination Approaches: Targeting CHEK2 together with other DNA repair proteins may enhance neuroprotection [10].
CHEK2 and its phosphorylation status show potential as:
| Model | CHEK2 Status | Phenotype | Reference |
|---|---|---|---|
| Chek2 knockout mice | Complete loss | Viable, tumor-prone | [1:1] |
| Conditional neuronal KO | Neuron-specific deletion | Increased DNA damage, cognitive deficits | [4:1] |
| AD model with CHEK2 loss | Genetic interaction | Accelerated pathology | [11] |
| PD model | CHEK2 activation | Dopaminergic neuron loss | [8:1] |
| Substrate | Function | Neuronal Relevance |
|---|---|---|
| CDC25A/B/C | Cell cycle phosphatases | Cell cycle re-entry control |
| p53 (TP53) | Tumor suppressor | Apoptosis regulation |
| BRCA1 | DNA repair | Homologous recombination |
| E2F1 | Transcription factor | Cell cycle/gene expression |
| PLK1 | Mitotic kinase | Mitosis control |
| KAP1 | Chromatin regulator | DNA repair gene expression |
Ahn et al., CHEK2 kinase activity regulation (2004). 2004. ↩︎
Bartek & Lukas, CHK1 and CHK2 in DNA damage response (2003). 2003. ↩︎
Lee et al., CHEK2 in neuronal DNA damage response (2014). 2014. ↩︎ ↩︎
Madabhushi et al., Activity-induced DNA damage in neurons (2014). 2014. ↩︎
Schafer et al., Mitochondrial dysfunction and DNA damage (2018). 2018. ↩︎
Boehm et al., CHK2 inhibitors in neuroprotection (2022). 2022. ↩︎
Herbert et al., Therapeutic targeting of DNA damage response in neurodegeneration (2022). 2022. ↩︎
Krishnan et al., DNA damage in Alzheimer's disease (2018). 2018. ↩︎